Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series

Acta Derm Venereol. 2022 Sep 28:102:adv00780. doi: 10.2340/actadv.v102.2926.
No abstract available

MeSH terms

  • Antibodies, Monoclonal / adverse effects
  • Hidradenitis Suppurativa* / diagnosis
  • Hidradenitis Suppurativa* / drug therapy
  • Humans

Substances

  • Antibodies, Monoclonal
  • risankizumab